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Summary Background: Cardiac involvement in muco-
polysaccharidosis type I (MPS I) has been studied
primarilyin its most severe forms. Cardiac involvement,
particularly left ventricular (LV) systolic and diastolic
function, in the attenuated form of MPS I is less well
known. Methods: Cardiac function was prospectively
investigated in 9adultpatients with the attenuated form
of MPS I. All patients underwent 12-lead electrocardi-
ography, 24 h Holter monitoring and two-dimensional
echocardiography including tissue Doppler imaging
(TDI). Eighteen age- and sex-matched healthy volun-
teers served as a control group. Results: Aortic, mitral
and tricuspid valve thickening was seen in, respectively,
5 (56%), 4 (44%) and 2 (22%) patients. Moderate
mitral valve stenosis was seen in 1 patient and
moderate aortic stenosis in 2 patients. All patients
had mild-to-moderate aortic and mitral valve regurgi-
tation and 6 patients (67%) had mild-to-moderate
tricuspid valve regurgitation. Despite normal LV
dimensions, ejection fraction and mass index, MPS
patients had lower mean systolic mitral annular veloc-
ities (6.1T0.6 vs 9.1T1.4 cm/s, p<0.01) compared to
normal control subjects. Similarly, mean early diastolic
mitral annular velocities were lower in MPS patients
(7.8T0.9 vs 13.3T3.3 cm/s, p<0.01). Conclusion: MPS I
patients with the attenuated phenotype have not only
valvular abnormalities but also LV diastolic and
systolic abnormalities.
Abbreviations
Em mitral annular peak early diastolic velocity
GAGs glycosaminoglycans
!-IDUA !-L-iduronidase
LV left ventricular
MPS mucopolysaccharidosis
Sm mitral annular peak systolic velocity
TDI tissue Doppler imaging
Introduction
M u c o p o l y s a c c h a r i d o s i st y p eI( M P SI )i sar a r e
autosomal recessive disease caused by deficiency of
the lysosomal enzyme a-L-iduronidase (a-IDUA). This
enzyme is involved in the degradation of sulfated
glycosaminoglycans (GAGs) and deficiency results in
intracellular accumulations of the GAGs heparin
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2001). Deficiency of a-IDUA gives rise to three main
classical clinical entities—Hurler syndrome, presenting in
infancy and the most severe phenotype; Hurler–Scheie
syndrome, a phenotype presenting in childhood of inter-
mediate severity; and Scheie syndrome, the mildest form
of MPS I. Because of the great overlap between patient
groups (which cannot be distinguished by either enzyme
deficiency or urinary GAGs), it may be more appropriate
to categorize the patients into attenuated and severe
forms of MPS I (Vijay and Wraith 2005). Cardiomyopa-
thy and thickening of cardiac valves and large vessels
have been described in MPS I patients, especially in the
most severe form (Braunlin et al 2006a,b; Dangel 1998;
Nelson et al 1990). Cardiac involvement in the attenuated
form of MPS I is less well known. We therefore
prospectively studied cardiac involvement in a series of
patients with the attenuated form of MPS I.
Methods
Study population
A standard programme was initiated to prospectively
investigate cardiac involvement and function in 9 adult
patientswiththeattenuatedformofMPSIwhowerenot
treated with enzyme replacement therapy or bone
marrow or cord blood transplantation. The diagnosis of
MPS I was based on demonstrating a deficiency of
a-IDUA activity in cultured fibroblasts together with
increased urinary levels of GAGs. All patients gave
informed consent before participating into the study,
which included clinical assessment, 12-lead electrocardi-
ography, Holter monitoring and two-dimensional echo-
cardiography including tissue Doppler imaging (TDI).
Two-dimensional echocardiography
Echocardiographic studieswereperformedwithaSonos
7500 ultrasound system (Philips, Best, The Netherlands)
equipped with an S3 transducer (frequency 1–3.2 MHz)
by a single, experienced sonographer (W.B.V.). Images
were sent digitally to a remote workstation with
EnConcert software (Philips) for offline analysis.
Cardiac dimensions and Doppler parameters were mea-
sured using electronic callipers and computed by pre-
installed standard formulae.
Valvular anatomy and function
For assessment of valvular thickness, fundamental
imaging at a frequency of 2–3 MHz was used with a
zoom function applied to the valve region and optimal
gain settings. Based on normal values for mitral and
aorticvalve leaflet thickness(rangingfrom 0.7to 3.0and
from 0.7 to 2.0 mm, respectively) (Crawford and Roldan
2001; Weissman et al 1994), abnormal valve leaflet
thickness was defined as a thickness >3.0 mm for the
mitral valve or >2.0 mm for the aortic valve. Valvular
peak and mean gradients were calculated from the
continuous-wave Doppler transvalvular velocities using
the Bernoulli equation (Otto 2004). Valvular regurgita-
tion was graded as absent, mild, moderate or severe on a
semi-quantitative scale using standard colour Doppler
and continuous-wave Doppler parameters according to
the recommendations of the American Society of
Echocardiography (Zoghbi et al 2003).
Cardiac dimensions
For better endocardial border definition, second-
harmonic imaging was used (transmitted frequency
1.6 MHz, received frequency 3.2 MHz). Assessment of
left atrial dimension, left ventricular (LV) wall thick-
ness, LV end-diastolic and end-systolic dimensions
and LV mass index was done as described before
(Vydt et al 2007).
LV systolic function
Non-foreshortened apical 2- and 4-chamber views
were used for assessment of LV end-diastolic and
end-systolic volumes. LV ejection fraction was calcu-
lated by the modified bi-plane Simpson according to
the recommendations of the American Society of
Echocardiography (Cheitlin et al 1997; Lang et al
2006). In addition, systolic mitral (Sm) annular peak
velocities were measured with TDI from the infero-
septal and anterolateral wall. Subsequently, mean Sm
(calculated from these two walls) was calculated.
Normal values for LV ejection fraction and mean Sm
were derived from 18 age- and sex-matched volunteers
with normal left atrial and LV dimensions and LV
function as described before (Nikitin et al 2003). The
normal lower cut-off value (meanjSD) for LV
ejection fraction was 50% and for mean Sm was
7.7 cm/s.
LV diastolic function
The assessment of LV diastolic function was based
on a combination of end-expiratory pulsed-wave
Doppler mitral inflow velocity, pulmonary venous
flow and mitral annular TDI recordings, according to
the recommendations of the American Society of
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pulsed-wave Doppler mitral inflow velocities, a sample
volume was placed at the tips of the mitral leaflets with
a minimized angle between mitral inflow and the
Doppler beam. From the velocity tracing obtained,
peak early diastolic transmitral flow velocity (E), peak
late diastolic transmitral flow velocity (A), early filling
deceleration time (DT), and A-wave duration were
measured. To measure pulmonary flow velocities, a
sample volume was placed at the right paraseptal
pulmonary vein in the apical 4-chamber view. Systolic
(S) and early diastolic (D) velocities and the duration
of late atrial reversed (AR) diastolic flow were
measured. TDI was applied in the pulsed-wave
Doppler mode at the level of the mitral annulus in an
apical 4-chamber view. From the velocity tracing
obtained, the inferoseptal and anterolateral early di-
astolic mitral (Em) annular peak velocities were mea-
sured. Subsequently, mean Em (calculated from these
two walls) and the dimensionless ratio of early mitral
inflow peak velocity to early mitral annular peak
diastolic velocity (E/Em) were calculated. All de-
scribed measurements were averaged from 3 samples.
Based on these three methods, normal LV diastolic
function was defined as a combination of E/A ratio
between 0.75 and 1.50, DT between 150 and 220 ms,
pulmonaryS>D,ARduration<A-waveduration+30ms,
mean Em>10.0 cm/s, and E/Em<9. Stage I diastolic
dysfunction (impaired LV relaxation) was defined as E/A
ratio<0.75 and DT>220 ms. Stage II diastolic dysfunc-
tion (pseudo-normal LV filling) was defined as an E/A
ratio between 0.75 and 1.5 with a mean Em<7 cm/s and
E/Em>15. Stage III diastolic dysfunction (restrictive LV
filling) was defined as E/A ratio>1.5 with a DT<150 ms,
mean Em<7 cm/s, and E/Em>15 (Khouri et al 2004;
Nagueh et al 1997; Ommen et al 2000).
Statistical analysis
To compare TDI mean values between patients and
controls, the independent t-test was used. A p-value<0.05
was considered significant. All statistics were performed
using SPSS (12.0.2) for Windows package (SPSS, Inc.,
Chicago, IL, USA).
Results
Patient population
The mean age of the patients was 32T7 years, 6 were
male. The clinical features of the MPS I patients
studied are summarized in Table 1. Patients 3 and 5
are brother and sister, and patients 4, 7, 8 and 9 are
siblings.
Clinical characteristics
None of the patients had a history of palpitations,
shortness of breath, chest pain or other symptoms of
suspected cardiac origin. From a cardiovascular
point of view, all patients were thus in NYHA class
I. The presenting symptoms were joint stiffness in 6
patients (nos. 1, 4, 6, 7, 8 and 9), dysmorphy in 2
patients (nos. 2 and 3) and growth retardation in 1
patient (no. 5).
Electrocardiographic abnormalities
Apart from one patient (patient no. 2) with atrial
tachycardia 218 beats/min with 2:1 atrioventricular
block, right axis deviation, and electrocardiographic
evidence of right ventricular hypertrophy (confirmed
Table 1 Clinical characteristics of MPS patients with the attenuated phenotype
Patient
number
Age
(years)
Sex Weight
(kg)
Height
(cm)
a-L-Iduronidase
activity
a
Urinary
GAGs
b
Joint
stiffness
Corneal
clouding
Hepatosplenomegaly
c Age of
clinical symptoms
(years)
1 21 M 56 158 0.3 16.2 + + + 11
2 22 M 37 140 0.0 74.7 + + + 0
3 26 F 50 150 0.0 49.5 + + + 0
4 28 M 75 171 0.0 10.4 + + j 4
5 31 M 71 165 0.0 22.6 + + + 3
6 31 F 52 158 0.0 NA + + j 3
7 32 M 71 166 0.0 11.5 + + j 4
8 39 F 68 157 0.0 13.9 + + j 4
9 43 M 88 168 0.4 NA + + j 4
anmol/h per mg, normal range 25–90.
bmg/mmol creatinine, normal adult range <12.2.
cOn abdominal ultrasound examination.
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Patient number Thickening (mm) Transvalvular peak (Beesley et al 2001) gradient
(mmHg)
Regurgitation (severity)
Mitral Aortic Tricuspid Mitral Aortic Tricuspid Mitral Aortic Tricuspid
1 4.3 2.2 3.4 7.0 (4.0) 9.0 (6.0) 1.9 (1.0) Mod-E Mild-C Mild
2 5.7 4.3 6.2 9.8 (6.0) 23.0 (15.0) NA Mod-E Mild-C Mod
3 4.7 2.2 2.7 8.7 (3.0) 9.7 (5.0) 4.1 (1.8) Mod-E Mod-E Mod
4 2.2 1.7 1.1 3.4 (1.3) 7.3 (4.0) NA Mild-C Mod-C Trivial
5 6.3 3.2 2.0 5.3 (3.0) 8.8 (5.0) 1.9 (0.8) Mod-E Mod-C Mod
6 2.5 1.9 2.6 3.9 (1.3) 6.1 (3.4) 1.6 (1.1) Mod-E Mod-C Mild
7 2.8 1.8 2.5 2.8 (1.3) 8.4 (3.4) NA Mild-C Mod-C Mild
8 2.8 2.0 1.7 3.2 (1.5) 11.0 (6.0) 1.2 (0.6) Mod-C Mod-C Trivial
9 2.2 2.1 2.1 5.7 (2.3) 27.0 (16.0) NA Mod-E Mod-C Trivial
Abnormal values are printed in bold.
C, central jet; E, eccentric jet; Mod, moderate; NA, not available.
Normal valve thickness values are for mitral and tricuspid valve leaflets <3.0 mm and for aortic valve leaflet <2.0 mm.
Normal pressure gradient values are for mitral valve mean gradient <5.0 mmHg and for aortic valve mean gradient <7.0 mmHg.
Fig. 1 Echocardiographic signs of cardiac involvement in patient
(no. 1) with mucopolysaccharidosis type I: thickened mitral and
aortic valve leaflets in parasternal long-axis view (A); thickened
tricuspid valve leaflets in apical 4-chamber view (B); thickened
mitral valve leaflets in parasternal short-axis view (C); mitral
regurgitation jet in parasternal long-axis view (D); aortic
regurgitation jet in apical long-axis view (E); and mitral annular
velocity profile (F) from septal annulus (upper panel) and from
lateral annulus (lower panel)
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ography), no abnormalities were found on the 12-lead
electrocardiography. All other 8 patients had normal
sinus rhythm, electrical axis, conduction times, QRS
complex and repolarization. During 24 h Holter moni-
toring, no further conduction abnormalities or arrhyth-
mias were seen.
Valvular function
As seen in Table 2, aortic, mitral and tricuspid valve
thickening was seen in, respectively, 5 (56%), 4
(44%), and 2 (22%) patients. Mild mitral valve
stenosis was seen in 1 patient and mild aortic stenosis
in 2 patients. All patients had mild-to-moderate aortic
and mitral valve regurgitation and 6 patients (67%)
had mild-to-moderate tricuspid valve regurgitation.
Examples of echocardiographic abnormalities in
patient 1 are displayed in Fig. 1.
Systolic function
As seen in Table 3, LV dimensions, ejection fraction
and mass index were normal in all patients. Systolic
mitral annular velocities were abnormal in all patients
in whom these measurements were available; mean
systolic mitral annular velocity in MPS patients was
lower than in the normal control subjects (6.1T0.6 vs
9.1T1.4 cm/s, p<0.01).
Diastolic function
As seen in Table 3, early diastolic mitral annular
velocities were abnormal in all patients in whom these
measurements were available; mean early diastolic
mitral annular velocity in MPS patients was lower than
in the normal control subjects (7.8T0.9 vs 13.3T3.3 cm/s,
p<0.01). When all three different diastolic dysfunction
parameters were included (mitral inflow, pulmonary
venous flow, and mitral annular velocity), two patients
(nos. 2 and 9) had overt diastolic dysfunction (grade II
or pseudo-normalization).
Discussion
Cardiovascular manifestations in children and adults
with MPS I include arrhythmias (Vijay and Wraith
2005), atrioventricular heart block (Kakkis et al 2001),
valvular involvement (Dangel 1998; Rigante and Segni
2002; Wippermann et al 1995) and hypertrophic
cardiomyopathy (Dangel 1998; Mohan et al 2002;
Rigante and Segni 2002). Valvular and muscular
findings in studies and case reports that included MPS
I patients with the attenuated form are summarized in
Table 4. Unfortunately, only limited information is
availableonpatientswith theattenuatedformof MPSI.
As seen in Table 4, mild valvular thickening with
stenosis and regurgitation was reported in most patients
with the attenuated form of MPS I. Severe mitral or
aortic stenosis necessitating surgery has been described
in case reports (Butman et al 1989; Fischer et al 1999).
In contrast, systolic LV function was described as
normal in these patients (Braunlin et al 2006a,b; Dangel
1998; Fischer et al 1999; Minakata et al 1998; Mohan
et al 2002; Sifuentes et al 2007).
In our study, 9 adult patients with the attenuated
form of MPS I but without known manifestations of
Table 3 Functional echocardiographic data
Patient
number
LA size
(mm)
LV mass index
(g/m
2)
LV-EDD
(mm)
LV-EF
(%)
Diastolic
grade
Mean Sm
(cm/s)
Mean Em
(cm/s)
Mean
E/Emratio
1 38 127 52 69 0 6.0 7.0 14.5
2 61 124 45 64 II NA NA NA
3 30 83 44 69 0 NA NA NA
44 2 9 0 5 1 5 9 0 7.0 8.9 9.3
5 33 86 46 69 0 NA NA NA
63 7 9 4 4 5 6 7 0 5.2 8.1 12.3
74 0 6 8 4 7 6 3 0 5.9 8.5 10.0
83 3 6 5 4 4 5 7 0 6.0 7.0 11.6
9 43 115 53 63 II 6.3 6.5 15.0
Abnormal values are printed in bold.
LA, left atrial; LV, left ventricular; EDD, end-diastolic diameter; Sm, systolic mitral annular velocity; E, early filling wave of mitral
inflow; Em=early diastolic mitral annular velocity. NA=not available.
Normal values in age- and sex-matched adults: LA size <44 mm; LV-EDD <58 mm; LV mass index in men e150 g/m
2, in women
e120 g/m
2; LV-EF >50%; mean Sm>7.7 cm/s; mean Em>10.0 cm/s; E/Em ratio <8.
Grade II diastolic dysfunction means evidence for pseudo-normalization of LV filling pressure.
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valvular regurgitation was seen in all patients, in
particular of the aortic and mitral valves. Most patients
had also evidence for valvular thickening; significant
gradients were seen in 3 patients. These findings are
consistent with previously published data (Dangel
1998; Rigante and Segni 2002). In histological studies
in mice, enlarged and misshapen heart valves contain-
ing large numbers of highly vacuolated interstitial cells
have been described (Jordan et al 2005). Despite
normal LV ejection fraction, we describe for the first
time subclinical systolic and diastolic LV dysfunction.
This was evidenced by reduced systolic and early
diastolic mitral annular velocities reflecting impaired
longitudinal LV function. Abnormal systolic longitu-
dinal LV function is an early marker for LV dysfunc-
tion and may be present at stages in which radial
function may be normal or even compensatorily
increased in the early stages of disease (Marwick
2004). We and others have reported early signs of
systolic LV dysfunction in patients with diabetes,
hypertension and storage or neuromuscular diseases
(Marwick 2004; Poulsen et al 2003; Vydt et al 2007)
Of note, none of our patients had diabetes or
hypertension. Thus far, systolic LV myocardial in-
volvement has been described only in patients with the
severe MPS Hurler syndrome (Dangel 1998; Mohan
et al 2002). In severely affected mice, infiltration of
cardiac muscle by storage-laden cells has been shown
histologically (Jordan et al 2005). Also, diastolic
function seems abnormal in our MPS I patients with
the attenuated phenotype, as evidenced by abnormal
Em velocity and increased E/Em ratios, corresponding
to increased LV filling pressures (Nagueh et al 1997;
Ommen et al 2000). Of note, most patients had mild-
to-moderate mitral regurgitation and this may be a
confounding factor in the assessment of E/Em ratio.
However, it was shown that in primary mitral regurgi-
tation (due to intrinsic valvular disease such as in
MPS I), in contrast to secondary mitral regurgitation
(caused by LV and/or mitral annular enlargement), the
E/Emratioisnotsignificantlyincreased(Bruchetal2004).
Limitations
Echocardiographic measurement of valvular thick-
nesses is difficult, and literature-derived normal values
are heterogeneous. Usually, mitral and tricuspid leaflet
thickness >3 mm is considered abnormal in both
transthoracic and transoesophageal echocardiography
(Crawford and Roldan 2001; Weissman et al 1994).
The measured thickness may be greater than the
actual thickness because of the gain settings, poor
resolution in the far field, the ultrasound transit time
being slower in the dense, fibrocalcific structures than
in soft tissue, and the ultrasound frequency. Although
the thickness of the anterior mitral leaflet, particularly
its middle part, can be measured relatively easily by
two-dimensional echocardiography, the thickness of
the posterior leaflet may be more difficult to measure
because of the shortness of the leaflet and the
numerous attachments of the chordae tendineae
(Sahasakul et al 1988).
Table 4 Summary of studies that included patients with the attenuated form of MPS I
Authors (year) Patient numbers Attenuated form (Scheie)
Hurler Hurler–Scheie Scheie Valvular involvement Muscle function Muscle mass
Sifuentes et al (2007)
a 0 4 1 Yes 6 j
Braunlin (2006a,b) 2 0 3 Yes 6 j
Vijay and Wraith (2005) 0 19 10 Yes j 6
Mohan et al (2002) 29 0 2 Yes 66
Kakkis et al (2001) 1 8 1 Yes jj
Fischer et al (1999) 0 0 1 Yes 66
Dangel (1998) 5 0 2 Yes 66
Minakata et al (1998) 0 0 2 Yes 6 j
Wippermann et al (1995) 12 0 6 Yes jj
Masuda et al (1993) 0 0 1 Yes jj
Butman et al (1989) 0 0 1 Yes jj
Tada et al (1983) 0 0 1 Yes jj
Fujiwara et al (1983) 0 0 1 Yes jj
6, normal; j, increased; j, data are not available.
aLong-term follow-up of the series by Kakkis et al (2001).
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MPS I patients with the attenuated phenotype have,
apart from valvular abnormalities, also LV diastolic
and systolic abnormalities. Currently, no information
is available about the progression in time of these
diastolic and systolic abnormalities. Until such data
are available, routine TDI measurements cannot be
recommended. Nevertheless, all MPS I patients with
the attenuated phenotype should undergo a baseline
echocardiographic examination, and until specific
information about cardiac disease progression is
available should be followed-up according to the
available (valvular) guidelines since the described
cardiac abnormalities may have important therapeutic
and prognostic consequences (Zoghbi et al 2003).
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